Collegium Pharmaceutical
COLL
267 hedge funds and large institutions have $1.26B invested in Collegium Pharmaceutical in 2026 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 108 increasing their positions, 77 reducing their positions, and 46 closing their positions.
86% more capital inflows, than outflows
Capital inflows: $292M | Capital outflows: $157M
40% more repeat investments, than reductions
Existing positions increased: 108 | Existing positions reduced: 77
1.14% more ownership
Funds ownership: 115.52% → 116.66% (+1.1%)
9% less first-time investments, than exits
New positions opened: 42 | Existing positions closed: 46
4% less funds holding
Funds holding: 278 → 267 (-11)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$17.6M |
| 2 |
Janus Henderson Group
London,
|
+$16M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$15M |
| 4 |
Millennium Management
New York
|
+$12.3M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$19.1M |
| 2 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$9.59M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$9.18M |
| 4 |
Jane Street
New York
|
-$8.83M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$8.43M |
COLL Hedge Fund Activity: Q1 2026 in Review
267 of the 8,210 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q1 2026, worth a combined $1.26B — down 27% from $1.72B a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of COLL and 42 opened new positions — a net loss of 4 holders — while 77 trimmed existing stakes and 108 added.
The largest buyer was Invesco, adding an estimated $17.6M. The largest seller was Eventide Asset Management, cutting an estimated $19.1M.
- 267 institutional investors held Collegium Pharmaceutical (COLL) as of Q1 2026, down from 278 in Q4 2025.
- Funds reported $1.26B of Collegium Pharmaceutical stock for Q1 2026, down 27% quarter-over-quarter.
- 42 funds opened new Collegium Pharmaceutical positions in Q1 2026 and 46 closed out, a net change of -4 holders.
- The largest Collegium Pharmaceutical buyer in Q1 2026 was Invesco, an estimated $17.6M added.
- The largest Collegium Pharmaceutical seller in Q1 2026 was Eventide Asset Management, an estimated $19.1M sold.
Based on aggregated 13F filings for Q1 2026.